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IgG3
Activates complement and FcγR-mediated functions more efficiently than other IgG subclasses, although also more susceptible to proteolysis and exhibits a shorter half-life. However, a recent study identified an allotype that exhibits a considerably longer half-life (Stapleton et al, 2011).
Change heavy chain
IgA, IgE, IgM 
Optimize fusion partner

Vaccine
With monomeric fusions, use of an Ag that recognizes receptors on APCs would enable cross-linking with FcγRs, which is required for a well-balanced immune response. The fusion partner can also affect binding to FcγRs (Mekhaiel et al, 2011b ).
Increase valency
Expected to be generally useful strategy to increase potency of therapy and enable binding to receptors that only bind polymeric ICs, for example FcRL4 & FcRL5. Successful strategies include biosynthetic hexameric complexes (Mekhaiel et al, 2011b) and IgM-based complexes (Ammann et al, 2012).
